Background : Study on epigenetics of urothelial carcinomas has expanded and allowed better understanding of their correlation with clinicopathologic features. The aim of this study was to determine reliable predictive epigenetic markers for patients with urothelial carcinoma of urinary bladder. Methods : In 64 urothelial carcinomas of the urinary bladder, methylationspecific polymerase chain reaction with RAS association domain family 1A (RASSF1A), adenomatous polyposis coli (APC), death-associated protein-kinase (DAPK), runt-related transcription factor 3 (RUNX3), p14, p16 and MGMT was performed and correlated the results with p53 mutations, DNA ploidy, clinicopathologic parameters and recurrences. Results : Hypermethyation of RASSF1A, APC, DAPK, RUNX3, p14, p16 and MGMT promoters was observed in 35 (54.7%), 29 (45.3%), 18 (28.1%), 18 (28.1%), 9 (14.1%), 2 (3.1%), and 6 (9.4%) cases, respectively. Hypermethylation of RUNX3 and APC was significantly associated with high histologic grades and aneuploidy. Methylation of DAPK was significantly associated with muscle invasion. Methylation of DAPK and RUNX3 genes was significantly associated with recurrence. In survival analyses, methylation of RUNX3 gene and methylation-high (methylation at two or more loci) phenotype was significantly associated with poor recurrence-free survival. Conclusions : Methylation of RUNX3 gene and methylation-high phenotype are significant indicator of recurrence.
Urinary bladder cancer is the fifth most common cancer in the Western world and is responsible for about 3% of all cancer-related deaths.
1 Urothelial (transitional cell) carcinoma, the most common carcinoma of the urinary tract, is a disease of the entire urothelium and is characterized by multiplicity. Although urothelial carcinoma can be removed by transurethral resection, more than 50% of cases will experience recurrence.
2
Hypermethylation in CpG islands of growth-regulating gene promoter regions is now recognized as a common alternative mechanism for gene inactivation in human cancer, an event as important as somatic mutations in the coding regions of tumor suppressor genes. 3, 4 Hypermethylation of CpG islands has also been detected in urothelial carcinoma of the bladder. [5] [6] [7] [8] [9] In urothelial carcinomas, hypermethylation of CpG islands around the promoter region and decreased expression of tumor suppressor genes including death-associated protein-kinase (DAPK), RAS association domain family 1A (RASSF1A), adenomatous polyposis coli (APC), runt-related transcription factor 3 (RUNX3), p16, retinoic acid receptor beta, and E-cadherin have been reported. 6, 8, 10, 11 Inactivation of RUNX3 through promoter hypermethylation is associated with invasion, progression, and poor prognosis. 8 Methylation of the DAPK promoter has been found in 4% to 58.2% of urinary bladder carcinoma cases and is associated with higher tumor stages, higher grades, and muscle invasiveness.
6,12-15 APC hypermethylation is associated with malignant behavior and worse outcomes. 16, 17 Promoter hypermethylations of RASSF1A and p14 appear to be initial events in urinary bladder carcinogenesis, which are maintained during tumor progression. 3, 18 p53 is a key player in tumor suppression, as it promotes growth arrest, apoptosis, and cellular senescence and blocks angiogenesis.
19 p53 mutations provide precancerous cells with a selective advantage for unregulated growth and the acquisition of genetic instability. 20 Alterations in tumor suppressor p53 in bladder cancer, which are known to decrease genetic stability, are associated with higher grades, later stages, and worse patient outcomes.
21
Aberrant promoter methylation has been described for several genes in various malignant diseases and is associated with tumor progression. Further, each tumor type may have its own distinct pattern of methylation.
6 Selection of appropriate clinically significant methylation markers will help predict the aggressiveness of bladder carcinomas. Although hypermethylation of specific genes has been extensively investigated in urothelial carcinomas of the bladder, 5, 8, 10, 13, 14, 22 a multiple gene methylation profile is lacking and has never been studied in Korean populations. 11, 13, 23 Establishing DNA methylation profiles for bladder carcinoma might provide valuable markers for predicting prognosis.
For this purpose, we selected seven genes frequently silenced by aberrant methylation in a number of tumor types to investigate the methylation profile of bladder cancer. We correlated our findings with p53 mutations, DNA ploidy, and clinicopathological parameters in patients with bladder carcinoma.
MATERIALS AND METHODS

Patient selection
We randomly selected 64 patients diagnosed with urothelial carcinoma of the urinary bladder at Samsung Medical Center, Seoul, Korea between 1998 and 2003, who had undergone clinical follow-up. All patients had a histological diagnosis of urothelial carcinoma. A complete transurethral resection of the bladder tumor was performed in cases of superficial bladder tumors. Patients with superficial bladder tumors received one cycle of intravesical treatment (bacillus Calmette-Guerin or mitomycin). A radical cystectomy and complete pelvic lymph node dissection were performed for invasive bladder tumors.
The median age at the time of diagnosis was 65 years (range, 36 to 81 years); seven (10.9%) patients were female and 57 (89.1%) were male. All tumors were diagnosed according to American Joint Committee on Cancer staging and were divided into low grade (n = 23) and high grade (n = 41). 24 The depth of invasion was categorized as noninvasive (pTa, n = 25), superficial (pT1, n = 24), or deeply invasive (pT2 to T4, n = 15) carcinoma (Table 1) .
Follow-up was available in all cases. Recurrence of disease was observed in 29 patients (45.3%) and distant metastasis was observed in ten cases (15.6%). The median follow-up was 62.0 months (range, 6.0 to 141.0 months).
Bisulfite modification and methylation-specific polymerase chain reaction Genomic DNA was extracted from paraffin-embedded tumor tissue using manual microdissection, standard proteinase K digestion, and a QIAamp DNA mini kit, according to the manufacturer's instructions (Qiagen, Hilden, Germany). We used the EZ DNA Methylation kit for bisulfite modification, according to the manufacturer's protocol (Zymo Research Corp., San Diego, CA, USA). The modified DNA was subject to methylation-specific polymerase chain reaction (MS-PCR) using primers. Primer sequences, annealing temperatures, and the expected product size are listed in Table 2 . Bisulfate-modified DNA (2 mL) was amplified in a total volume of 10 mL containing 1× PCR buffer (Applied Biosystems, Foster City, CA, USA), 2 mM MgCl 2, 0.25 mM deoxynucleotide triphosphate, 1 mM of each primer, and 1 unit of AmpliTaq Gold polymerase (Applied Biosystems) at 95℃ for 10 minutes; 40 cycles of 95℃ for 30 seconds, the specific annealing temperature for 30 seconds, and 72℃ for 40 seconds; followed by a final extension at 72℃ for 10 minutes. Commercial methylated DNA (Chemicon, Temec- ula, CA, USA) was used as a positive control for methylation, and water was used as the negative control. PCR products (10 mL) were loaded onto nondenaturing 8% polyacrylamide gels that were then stained with SYBR green (Lonza, Rockland, ME, USA) and visualized under UV illumination.
p53 mutation and DNA ploidy Exons 5, 6, 7, and 8 of the p53 gene were examined for mutations using genomic DNA obtained from tumor tissue by PCRdirect sequencing methods (Table 2) . Genomic DNA (100 mg) was amplified in a total volume of 50 mL containing 1× PCR buffer (Applied Biosystems), 1.5 mM MgCl2, 0.25 mM deoxynucleotide triphosphate, 1 mM of each primer, and 1 unit of AmpliTaq Gold polymerase (Applied Biosystems) at 95℃ for 10 minutes; 35 cycles of 95℃ for 30 seconds, the specific annealing temperature for 30 seconds, and 72℃ for 40 seconds; followed by a final extension at 72℃ for 10 minutes. The purified PCR products (Bionics, Seoul, Korea) were directly sequenced, according to a dual DNA purification kit, using a BigDye Terminator v3.1 Cycle Sequencing kit, followed by analysis with an Applied Biosystems 3700 automated sequencer (Applied Biosystems).
Flow cytometric analyses were performed as previously described. 25, 26 Briefly, sections (5 mm) from each paraffin block were deparaffinized, according to the modified Hedley's method. Then, 1 mL of 0.5% prewarmed pepsin in 0.9% saline at pH 1.5 was added to each sample, followed by a 45-60 minute incubation at 36℃, with vortexing at intervals of 10 minutes. All residual solid tissue was then removed, and the remaining nuclear suspension was filtered through a 50 mm nylon mesh. The suspension was then centrifuged at 800 × g for 5 minutes, and the supernatant was decanted. The pellet was resuspended in 1 mL of Hanks' solution, centrifuged as before, and the supernatant was decanted. After disaggregation, the samples were stained with propidium iodide and analyzed using a BD FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA). The diploid tumors had a DNA index range of 0.95-1.05 to allow for a 5% instrument error.
Statistical analysis
The statistical analysis was performed with the SPSS ver. 16 (SPSS Inc., Chicago, IL, USA). The association between parameters was assessed using the c 2 test or Fisher's exact test. The recurrence-free interval and survival were analyzed according to the Kaplan-Meier method, and differences in their distribution models were evaluated by means of the log-rank test. A p-value U, unmethylated; M, methylated; DAPK, death-associated protein-kinase; RUNX3, runt-related transcription factor 3; APC, adenomatous polyposis coli; RASSF1A, RAS association domain family 1A. Table 2 . Primer sequences and polymerase chain reaction (PCR) conditions for methylation-specific PCR and p53 mutation analysis equal to or less than 0.05 was considered statistically significant.
RESULTS
The methylation statuses of seven loci were examined using MS-PCR in 64 bladder carcinoma samples. Hypermethylation of the RASSF1A, APC, DAPK, RUNX3, p14, p16, and MGMT promoters was observed in 35 (54.7%), 29 (45.3%), 18 (28.1%), 18 (28.1%), nine (14.1%), two (3.1%), and six (9.4%) cases, respectively. Fig. 1 shows the representative results of MS-PCR with the bladder carcinoma samples. Although the hypermethylation statuses of most genes were not related, methylation of the APC gene was significantly associated with methylation of the RASSF1A gene (p < 0.001).
The relationships between promoter hypermethylation and clinicopathological features were examined in urothelial carcinomas (Table 3) . Methylation of RUNX3 and APC was significantly associated with higher histological grade and aneuploidy (p < 0.05). Methylation of the DAPK and RUNX3 genes was more frequently observed in patients with recurrence or metastasis than in patients without recurrence (33.3% vs 20% and 30.8% vs 24.0%, respectively; p = 0.04). The DAPK gene promoter was significantly more methylated in carcinomas with muscle invasion than in carcinomas with superficial invasion or without invasion (60.0% vs 18.4%, respectively; p = 0.005).
Although MGMT methylation was rare, it was found solely and significantly in patients older than 65-years (p = DAPK, death-associated protein-kinase; APC, adenomatous polyposis coli; RUNX3, runt-related transcription factor 3. (Table 4) . Aneuploidy with chromosome abnormalities was observed in 28 of 64 patients (43.7%) and was closely associated with higher histological grade (0% vs 68.3%, respectively; p < 0.001) and deeper invasion (16.0% vs 61.5%, respectively; p = 0.001). Of 64 patients, 39 harbored p53 mutations (60.9%), although this was not related to histological grade, depth of invasion, or disease recurrence (p > 0.05). Promoter APC and RUNX3 hypermethylation was significantly associated with DNA ploidy and histological grade (p = 0.003 and p = 0.004, respectively). Moreover, cases with both RASSF1A methylation and p53 mutation were closely associated with DNA aneuploidy and higher histological grades (p = 0.01 and p = 0.04, respectively) ( Table 5 ).
DAPK
The univariate Kaplan-Meier analysis showed that pathological grade (p < 0.001) and depth of invasion (p = 0.03) were significantly associated with disease recurrence (Fig. 2) , and that RUNX3 gene methylation was significantly associated with reduced recurrence-free survival (p = 0.05). However, methylation of APC (p = 0.12) and DAPK (p = 0.80) was not associated with recurrence-free survival. When methylation of the three genes was grouped into methylation-low and methylation-high phenotypes, the methylation-high group showed a worse diseasefree survival than that of the methylation-low phenotype group (p = 0.01) (Fig. 3) .
DISCUSSION
In our comprehensive study of primary bladder urothelial carcinomas, the methylation profiles of tumor suppressor genes, including DAPK, RASSF1A, APC, RUNX3, p14, p16, and MGMT were investigated, and their associations with clinico-RUNX3, runt-related transcription factor 3; APC, adenomatous polyposis coli; DAPK, death-associated protein-kinase.
Parameter
No pathological parameters and disease recurrence were studied. We found that RUNX3 and APC gene methylation was significantly associated with higher histological grade and aneuploidy, DAPK methylation was significantly associated with muscle invasion, and DAPK and RUNX3 gene methylation was significantly associated with recurrence. In survival analyses, RUNX3 gene methylation and the methylation-high phenotype were significantly associated with reduced recurrencefree survival. Inactivation of DAPK occurs largely through transcriptional silencing via DNA hypermethylation and is involved in the process of bladder cancer development or invasion. 13 The frequency of DAPK methylation in urothelial carcinomas varies from 6% to 74%. 6, 7, 11, 13, 14 We observed DAPK methylation in 28.1% of cases, and this epigenetic alteration was closely associated with recurrence or metastasis. Our results confirmed the significance of DAPK methylation as one of the prognostic indicators for progression of bladder carcinomas.
RUNX3 methylation is an early event in bladder tumorigenesis, and its frequency increases over time. 27 In previous studies with Korean populations, RUNX3 methylation was observed in 71.2% and 73% of bladder urothelial carcinomas and was associated with invasive tumors, tumor progression, and poor survival. 5, 8 In our study, RUNX3 methylation was observed in 28.1% of cases. In previous studies in which fresh tissue was used (we used 8 to 12-year-old formalin-fixed paraffin-embedded tissue), the percentages of invasive tumors were 37.1% and 39.8% compared to the 23.4% observed in our study. This difference may be related to our lower frequency of RUNX3 methylation, which, although being lower than that in a previous report, was significantly associated with higher histological grade and DNA aneuploidy in our study. Maruyama et al. 6 reported that methylation of the APC gene was observed in 35% of bladder carcinomas and was correlated with high tumor grade and muscle invasion. In our results, APC methylation was observed in 45.3% of cases, similar to the frequency previously reported, and was associated with high histological grade and DNA aneuploidy. The lineage-specific tumor suppressor RUNX3 and the ubiquitous p53 protein are both principal responders of the p14 ARF -MDM2 cell surveillance pathway, which prevents pathological consequences due to abnormal oncogene activation. 28 Inactivation of cell-cycle regulation genes is associated with abnormal DNA ploidy. In our results, cell-cycle regulation genes such as APC and RUNX3 were more frequently methylated in patients with abnormal DNA ploidy. Furthermore, patients with aneuploidy were strongly associated with high histological grade, deep tumor invasion, and a subsequent poor prognosis. Our results suggest that methylation of APC or RUNX3 dysregulates cell-cycle arrest, generates aneuploidy, and may lead to tumor progression in human urothelial carcinoma. Densely methylated DNA associates with transcriptionally repressive chromatin characterized by the presence of underacetylated histones. 29 As these epigenetic events are reversible, they may be potential targets for agents that inhibit DNA methylation or histone deacetylation.
30 Both 5-azadeoxycytidine and histone deacetylase inhibitors have shown promising activity in clinical trials as single agents in patients with cancer. The future progress of this form of epigenetic cancer therapy will be followed with great interest.
30
Hypermethylation in the promoter regions of tumor suppressor genes is an early and frequent event associated with transcriptional silencing of regulatory genes during carcinogenesis.
3,4 The pathogenesis of cancer is attributable to multiple molecular changes, including gene mutations, changes in gene expression, protein functions, and other cellular processes.
As p53 is directly targeted in approximately 50% of human malignancies, 19 it has been suggested that other mechanisms are required to shutdown the p53 pathway in tumors with wildtype p53. A small but substantial proportion of bladder carcinomas demonstrate p53 nuclear reactivity but do not show detectable mutations in the p53 gene. 21 Recently, it was reported that inactivating the p53 pathway may contribute to increased promoter hypermethylation as a response to the increasing genomic instability and recombination events leading to alterations in chromatin structure and, thus, DNA methylation.
20
The p53 pathway plays an important role limiting the propagation of cultured aneuploid human cells to preserve the diploid karyotype of the population. RASSF1A can mediate cell-cycle arrest and senescence in human cancer cells through p53-independent regulation of p21 Cip 1/Waf . 30 In our study, p53 mutation and RASSF1A methylation were not associated with clinicopathological features or recurrence, in agreement with previous reports.
6,14,30 However, aneuploidy was significantly more frequent in patients harboring RASSF1A methylation and a p53 mutation, indicating that these genetic and epigenetic alterations may generate abnormal DNA ploidy and may involve progression of urothelial carcinoma.
In conclusion, RUNX3 gene methylation and a methylationhigh phenotype were significant indicators of poor recurrencefree survival. A p53 mutation and RASSF1A methylation may be involved in abnormal DNA ploidy and tumor progression in urothelial carcinoma of the bladder.
